Kornimate/medical-research-clean huggingface dataset:
diabetes reversal online program and study (drop study)

Conditions: Type 2 Diabetes

Summary: this is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. data will also be analyzed to see if participation in the program results in reductions glycated hemoglobin levels, body weight, and cholesterol levels.

this study aims to assess the feasibility and implementation of an online, plant-based, diabetes reversal program in a community setting. the study will also assess changes in glycated hemoglobin, body weight, and plasma lipids with an online 12-week, plant-based, nutrition education program. these health benefits may illustrate feasibility to physicians and healthcare professionals elsewhere, in addition to their value for the individual research participants.

Eligibility criteria:
inclusion criteria: * u.s. men and women meeting the age of majority, defined as follows: age 19 or older in nebraska and alabama; age 21 or older in mississippi; age 18 or older in all other states * prior diagnosis of type 2 diabetes mellitus exclusion criteria: * use of recreational drugs in the past 6 months * pregnancy or intention to become pregnant during the study period, as verified by self-report * unstable medical or psychiatric illness * lack of english fluency * inability to maintain current medication regimen * inability or unwillingness to participate in all components of the study

Keywords: plant-based vegan diet obesity
effect of aspirin preoperative on postoperative cognitive dysfunction in elderly patients undergoing knee arthroplasty

Conditions: Elective Surgery; Postoperative Cognitive Dysfunction; Knee Arthroplasty

Summary: studies have shown that the lifetime risk of developing symptomatic knee osteoarthritis is 40% in men and 47% in women; and the risk can be increased to 60% when the patient's bmi reaches 30 kg/m2. in this population, knee replacement is the most common, effective, and cost-effective method in all treatments with reducing pain, improving joint function and quality of life. postoperative cognitive dysfunction (pocd) is a common complication in the elderly, and its incidence can reach 25-40% in major non-cardiac surgery. as for pocd can prolong hospital stay, increase mortality and morbidity, and increase social and economic burden, it is especially important for the prevention and treatment of pocd. however, the mechanism of pocd is still unclear. studies suggest that it may involve inflammation and oxidative stress in the central nervous system. but for the elderly, they are in a state of low inflammatory response. at the same time, surgery and tourniquets also can trigger or aggravate inflammatory response. once the inflammatory factors released into the blood circulation, they can act on the central nervous system in a variety of ways. as a result,elderly patients are more likely to develop pocd. in addition, some studies have shown that pain can also increase cognitive burden. aspirin, its pharmacodynamic effects includes anti-inflammatory and analgesic effects which may have a certain effect on the prevention of pocd.

elderly patients undergoing knee replacement are more likely to develop pocd. the aim of this study is to determine the incidence of short-term pocd and long-term cognitive status in the elderly patients who use aspirin atleast three months before knee replacement.and then, the study evaluates the effect of aspirin on the incidence of postoperative delirium. in addition, it also shows the risk factors for pocd such as postoperative delirium, pain, c reactive protein and so on in the elderly patients who undergo knee replacement.

Eligibility criteria:
inclusion criteria: * age more than 60 years old undergoing elective knee replacement with general anesthesia * asa score grade i-iii * sign that informed consent is willing to participate in the study * can communicate in verbal * the time of using aspirin is at least 3 months exclusion criteria: * central nervous system disease; * mental illness before or now; * with using antipsychotic treatment such as sedatives or antidepressants; * with drug dependence; * severe visual, auditory, or motor impairment; * acute infection; * emergency surgery; * serious systemic diseases; * preoperative delirium and/ or cognitive dysfunction preoperative; * history of hospitalization 3 months before surgery. * participating in other research
detection of viral particels in urticaria patients

Conditions: Urticaria Chronic

Summary: blood samples from urticaria patients will be analyzed for viral particles

after digestion with dnase to eliminate human dna, rna will be reversed-transcribed and amplified with random primer/ amplification products will be pooled and sequenced/ after substruction of sequences of vertebrates and highly repetitive sequences, contiguous sequences will be assembled and compared with motifs represented in databases of viruses. which will enable identification of putative protein sequences consistent with viruses

Eligibility criteria:
inclusion criteria: * patients with chronic spontaneous urticaria exclusion criteria: * none
impact of von willebrand factor and its multimers on angiogenesis

Conditions: Von Willebrand Diseases

Summary: the study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von willebrand disease in order to try to identify markers of interest. secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.


Eligibility criteria:
inclusion criteria: for patients: * patient with von willebrand disease proven by genetic analysis of the vwf gene. * lack of treatment that could interfere with angiogenesis. * patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research. for the control: * patient with a normal coagulation report * absence of abnormal hemorrhagic symptoms * lack of notion of angiodysplasia. * lack of treatment that could interfere with angiogenesis. * patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research. exclusion criteria: * patient under guardianship or curatorship. * pregnant and lactating women. * blood transfusion or treatment with von willebrand factor concentrates less than 7 days old. * treatment which may interfere with angiogenesis.
cardiovascular an echocardiographic assessment in hypertension during pregnancy

Conditions: Pregnancy

Summary: cardiovascular \& echocardiographic assessment in pregnant women with hypertension during their pregnancy in comparison to pregnant normotensive women.

cardiovascular \& echocardiographic assessment in pregnant women with hypertension during their pregnancy in comparison to pregnant normotensive women. also,comparing echocardiographic parameters in hypertensive pregnant women being treated with either alfa methyl dopa or labetolol.

Eligibility criteria:
inclusion criteria: * hypertension during pregnancy: chronic or pregnancy induced exclusion criteria: * inability to sign informed consent

Keywords: hypertension pregnancy
safety and pharmacokinetics of recombinant factor xiii administration in healthy volunteers

Conditions: Congenital Bleeding Disorder; Congenital FXIII Deficiency; Healthy

Summary: this trial was conducted in europe. the aim of this trial was to investigate safety and pharmacokinetics of multiple doses of catridecacog (recombinant factor xiii, rfxiii) in healthy volunteers.


Eligibility criteria:
inclusion criteria: * normal platelet count and clotting parameters * adequate renal and hepatic function * negative serum pregnancy test within 21 days prior to enrollment and negative urine pregnancy test on admission to the clinical research unit (if subject female and of child-bearing potential) * agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits (if subject a sexually active male or female of childbearing potential) * negative drug and negative alcohol screens exclusion criteria: * known antibodies or hypersensitivity to fxiii * known bleeding or hematologic disorder * known allergy to yeast * receipt of blood products within 30 days of screening * donation of blood within 30 days prior to enrollment * surgical procedure of any type within 30 days prior to enrollment * history of autoimmune disorders involving autoantibodies, e.g., systemic lupus erythematosus * treatment with any experimental agent within 30 days of study enrollment
the effect of constructivist learning model based gynecological cancer education

Conditions: Gynecologic Cancer

Summary: this is a randomised controlled study.the study was conducted to determine the effect of the constructivist education model given to women on gynecological cancer awareness, health anxiety and spiritual well-being in women . the study population was composed of women living in kastamonu. women will be assigned to control and experimental groups. women in the control group will receive gynecological education from cancer early diagnosis, screening and education centers (ketem). the other group will receive gynecological cancer education based on the constructivist model.the hypotheses of the study are as follows: h0: the of constructivist learning model -based health education programme does not have an effect on gynecologic cancer awareness, spiritual well-being and health anxiety. h1: the of constructivist learning model -based health education programme have an effect on gynecologic cancer awareness, spiritual well-being and health anxiety.


Eligibility criteria:
inclusion criteria: * being 18 years old, * being willing to participate in this study exclusion criteria: * having any neuropsychiatric disorder, * having any physical or mental illness, * being diagnosed with gynecological cancer, * not attending theoretical trainings.
quinoa effects on glycemic index and satiety

Conditions: Overweight

Summary: the purpose of this study is to to assess the glycemic index and the satiating properties of different quinoa varieties, using a visual analogue scale in a sample of healthy overweight subjects.

pilot study to evaluate the glycemic index, and the satiating effect using different quinoa varieties in a group of healthy overweight subjects.

Eligibility criteria:
inclusion criteria: * men and women from 18 to 65 years old. * body mass index (bmi) ≥25 and \<30 kg/m2. * adequate cultural level and understanding for the clinical trial. * signed informed consent exclusion criteria: * individuals with bmi ≥30 or \<25 kg/m2 * vegetarians or individuals with a fiber intake ≥30 g/day * individuals diagnosed with diabetes mellitus * individuals with dyslipidemia on pharmacological treatment * individuals with hypertension on pharmacological treatment * smokers or heavy drinking individuals (\>2-3 servings/day in men and \> 1 serving/day in women (1 serving=1 glass of wine or 1 bottle of beer)) * individuals with large weight fluctuations or who have undergone in recent months a weight loss diet * individuals with gastrointestinal diseases that affect the digestion or the absorption of nutrients * individuals receiving at least the preceding 2 months a pharmacological treatment that modifies the lipid profile (for example, statins, fibrates, diuretics, corticosteroids, oral antidiabetic medications) * pregnant or breastfeeding women * women with menstrual irregularities (absence of menstrual cycle at least 2 months prior) * individuals with intense physical activity

Keywords: quinoa satiety visual analogue scale cross-over studies
the effect of virtual reality on postoperative pain and anxiety in cardiac surgery.

Conditions: Post Operative Pain; Post Operative Anxiety; Heart Surgery; Coronary Artery Bypass Grafting; Virtual Reality

Summary: the objective of this study is to investigate the effect of vr on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (cabg) procedure. participants in the intervention group will receive a 20 minute session with the head mounted vr device on post-operative days 1,2 and 3. participants in the control group will be treated with conventional post-operative care.

objective: the objective of this study is to investigate the effect of vr on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (cabg) procedure. study design: this study is a single-center randomized control trial. study population: patients who have undergone a cabg procedure (n=100). intervention: the intervention group (n=50) will use the vr distraction therapy device at day 1, 2 and 3 after surgery on the general ward. the control group (n=50) will be treated with conventional post-operative pain and anxiety management. main study parameters/endpoints: the main study parameters at day 1, 2 and 3 after surgery. these are the numeric rating scale (nrs) to assess the effect of pain on mobility, the quality of recovery-15 questionnaire, the state-trait anxiety inventory-6 questionnaire and assessment of analgesic use. at follow-up, participants will be called to gather one-time qor-15 and stai-6 questionnaire data 6 weeks after the surgery.

Eligibility criteria:
inclusion criteria: * age ≥18 years or older with written informed consent * patients undergoing surgical cabg exclusion criteria: * major comorbidities besides coronary artery disease * complicated surgical procedure * hearing and/or visual impairments * psychiatric impairments * complaints of vomiting and nausea * history of epilepsy * claustrophobia * facial wounds and skin defects at site of application * patients placed in clinical isolation * readmission to the intensive care unit
interest of flow cytometry for the diagnosis, the follow up and specific immunotherapy (sit) arrest of hymenoptera venom allergy

Conditions: Allergy

Summary: the aim of this study is to show that flow cytometry can be an accurate tool to help physicians regarding the diagnosis, the sit decision and the sit arrest of hymenoptera venom allergy. 75 patients having a story of reaction to hymenoptera venom will be selected for this trial. blood samples will be analyzed at: inclusion visit, week 1 visit, week 3 visit, week 10 and week 21 visit.


Eligibility criteria:
inclusion criteria: * adult patient (18 - 70 years) * patient being informed and accepting to participate in the study with signature of informed consent * patients having a clinical systematic and local, loco-regional story of reaction to the piqures of hymenopterans. * patients treated by sit for at least 5 years * patients benefiting from a national insurance health exclusion criteria: * children * pregnant woman or who breast-feed * patient under antihistaminic or corticoid for less than 8 days before the blood drawing * protected patient * patient not having given his agreement after it was informed
observational study to understand patients' and physicians' attitudes to statins in turkey

Conditions: Hypercholesterolemia

Summary: in turkey statin compliance is lower than eu countries. (eurika). we will assess the underlying causes of statin incompliance. the investigators will build patient and physician education programs to improve compliance in turkey. our aim is to assess patients' and physicians' attitudes to statins by mean of habit patient and physician survey respectively.

observational study to understand patients' and physicians' attitudes to statins in turkey

Eligibility criteria:
inclusion criteria: * provision of subject informed consent female and/or male aged over 18 years, * diagnosis of hypercholesterolemia according to icd-10 classification * receiving at least one prescription of one statin during the last 12 months and to be an outpatient. exclusion criteria: * receiving statin at the time of admittance * patients unable to read and/or understand the study questionnaires * pregnant women, * patients participating in randomized clinical trials and patients included in this study once

Keywords: statin hypercholesterolemia
the effect of emotional working memory training on preventing depression occurrence

Conditions: Depressive Symptoms

Summary: the purpose of this study is to test whether emotional working memory training and attention bias modification training are an effective neurobehavioral therapy to prevent the occurrence of depression .that is whether emotional working memory training and attention bias modification training are superior to placebo in preventing the occurrence of depression over 1 year after training.

attentional bias has been theorized to play a critical role in the onset and maintenance of depression. attentional bias modification training (abmt), an experimental paradigm that uses training to induce adaptive attentional bias, was developed to test the causal model and this has therapeutic implications in depression.to test the effect of abmt on treatment of depressive symptoms, a randomized, double-blind, placebo and blank controlled trial is conducted in college students who are experiencing mild-to-severe symptoms of depression.

Eligibility criteria:
inclusion criteria: * a score of 14 or higher on the beck depression inventory-ii. exclusion criteria: * a current episode of mdd, bipolar disorder, schizophrenia or organic mental disorder; * any concurrent psychotherapy; * any concurrent psychotropic medication.

Keywords: depression cognitive control emotion working memory cognitive bias emotional regulation
validation of a smartphone application for the assessment of patients with mild cognitive impairment: memscreen

Conditions: Cognitive Impairment; Alzheimer Disease

Summary: the clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions. the initial evaluation is made most often by a doctor (general practitioner). in case of need for further examination, a neuropsychological report is made in consultation memory by a neuropsychologist, with further cognitive tests. the cognitive neurology center at lariboisière hospital - fernand widal has developed a tool on a digital tablet or smartphone to evaluate cognitive functions: memscreen. the purpose of this study is to validate this new neuropsychological test on tablet compared to the neuropsychological reference tests.

characteristics of memscreen : * smartphone / tablet application developed by the cognitive neurology center at lariboisière - fernand widal hospital to explore a patient with a cognitive disorder. * the application is a self-test by the patient under the supervision of a doctor. * the doctor has an account to be able to pass the test to patients. * the tablet test is anonymous without the possibility to identify the patient.

Eligibility criteria:
inclusion criteria: * major patients followed in memory clinic. * performing a neuropsychological assessment less than 6 months old. * no visual or motor deficiency impeding the use of a digital tablet. exclusion criteria: * none.
belimumab in early systemic lupus erythematosus

Conditions: Lupus Erythematosus, Systemic

Summary: to investigate the efficacy of belimumab in early sle patients (disease duration less than 6 months).

this is a single arm, 24 weeks, pilot trial. all patients will be treated with standard of care plus belimumab (at a dose of 10 mg per kilogram of body weight) . the primary endpoint is the proportion of lldas in week 24.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of sle according to the 1997 american college of rheumatology (acr) classification criteria or 2019 eular/acr classification criteria within three months, which is autoantibody-positive (antinuclear antibody titers ≥1:80, anti-double-stranded dna antibodies, or both) * 18-75 years of age * body weight 45-80kg * disease duration of sle ≤ 6months * selena-2k score ≥6 scores * negative pregnancy test for child-bearing women at screening and baseline * provide written informed consent exclusion criteria: * known to be allergic to prednisone acetate, meprednisone, hydroxychloroquine, and immunosuppressants including mycophenolate mofetil, cyclophosphamide,et al * active serious neuropsychiatric systemic lupus erythematosus or other severe situations of sle who need pulse steroid treatment * abnormal liver function (alt or ast is 2 times higher than normal) * pregnancy or breastfeeding women; * have a history of malignant tumors; * have any serious acute, chronic or recurrent infectious disease (such as pneumonia or active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and tuberculosis) * chronic infections, such as hepatitis b virus or hepatitis b and c and hiv; * previous visual obstruction, monocular dysfunction and cataract; * cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic pressure \> 160mmhg or diastolic pressure \> 100mmhg) or diabetics; * active hemorrhage or peptic ulcer; * with other concommitant autoimmune disease; * receipt of b-cell-targeted therapy (including belimumab) within 1 year before randomization. * participated in other drugs clinical trials within 4 weeks.

Keywords: sle belimumab
a trial to evaluate the safety and pk profile of hrs4800 in healthy subjects

Conditions: Pain

Summary: the study will be conducted to evaluate the safety and pk profile of hrs4800 tablets after single oral administration in different dose levels compared to placebo.


Eligibility criteria:
inclusion criteria: 1. able to understand the purposes and risks of the trial and comply with all study procedures before entering the trial, and provide signed informed consent. 2. male aged between 18 years and 55 years at screening, inclusive. 3. total body weight ≥50 kg at screening, and body mass index (bmi) between 19.0 and 26.0 kg/m2, inclusive. 4. agree to take contraceptive measures and promise not to donate sperm since signing the informed consent form, to 3 months after the administration. 5. no clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function), and ecg, as determined by the investigator. exclusion criteria: 1. history of severe digestive system disease or having a digestive disease currently within 3 months of screening or before first dosing, and may affect drug absorption or have safety risks. 2. severe infections, injuries or surgeries within 3 months of screening or before first dosing, or plan to undergo any surgeries during the trial. 3. alt, ast, alp or total bilirubin level exceeds the upper limit of normal (uln) during screening/baseline visits. 4. subject's supine systolic bp is ≥140 mmhg or \<90 mmhg; diastolic bp ≥90 mmhg or \<60 mmhg at screening or before first dosing. 5. positive breath alcohol test after confirmation in a repeat test during screening/baseline visits. 6. positive drug screening tests,. 7. whole blood donation or loss of more than 200 ml of blood within 1 month prior to dosing; or blood donation or loss of more than 400 ml of blood within 3 months prior to dosing; or received blood within 2 months prior to dosing. 8. history of allergy to the study drug or any component of it.